TRPV2: A Cancer Biomarker and Potential Therapeutic Target
<p>The Transient Receptor Potential Vanilloid type-2 (TRPV2) channel exhibits oncogenicity in different types of cancers. TRPV2 is implicated in signaling pathways that mediate cell survival, proliferation, and metastasis. In leukemia and bladder cancer, the oncogenic activity of TRPV2 was lin...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , |
| Published: |
2020
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513563258781696 |
|---|---|
| author | Kodappully S. Siveen (4246150) |
| author2 | Parveen B. Nizamuddin (14590613) Shahab Uddin (14150949) Mohamed Al-Thani (14590614) Michael Paul Frenneaux (14590617) Ibrahim A. Janahi (14070765) Martin Steinhoff (5340194) Fouad Azizi (14152740) |
| author2_role | author author author author author author author |
| author_facet | Kodappully S. Siveen (4246150) Parveen B. Nizamuddin (14590613) Shahab Uddin (14150949) Mohamed Al-Thani (14590614) Michael Paul Frenneaux (14590617) Ibrahim A. Janahi (14070765) Martin Steinhoff (5340194) Fouad Azizi (14152740) |
| author_role | author |
| dc.creator.none.fl_str_mv | Kodappully S. Siveen (4246150) Parveen B. Nizamuddin (14590613) Shahab Uddin (14150949) Mohamed Al-Thani (14590614) Michael Paul Frenneaux (14590617) Ibrahim A. Janahi (14070765) Martin Steinhoff (5340194) Fouad Azizi (14152740) |
| dc.date.none.fl_str_mv | 2020-12-10T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1155/2020/8892312 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/TRPV2_A_Cancer_Biomarker_and_Potential_Therapeutic_Target/22058789 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Precision medicine Cancer biomarkers Tumor cell growth Oncogenicity Cancer progression Therapeutic targets Genetic alterations |
| dc.title.none.fl_str_mv | TRPV2: A Cancer Biomarker and Potential Therapeutic Target |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>The Transient Receptor Potential Vanilloid type-2 (TRPV2) channel exhibits oncogenicity in different types of cancers. TRPV2 is implicated in signaling pathways that mediate cell survival, proliferation, and metastasis. In leukemia and bladder cancer, the oncogenic activity of TRPV2 was linked to alteration of its expression profile. In multiple myeloma patients, TRPV2 overexpression correlated with bone tissue damage and poor prognosis. In prostate cancer, TRPV2 overexpression was associated with the castration-resistant phenotype and metastasis. Loss or inactivation of TRPV2 promoted glioblastoma cell proliferation and increased resistance to CD95-induced apoptotic cell death. TRPV2 overexpression was associated with high relapse-free survival in triple-negative breast cancer, whereas the opposite was found in patients with esophageal squamous cell carcinoma or gastric cancer. Another link was found between TRPV2 expression and either drug-induced cytotoxicity or stemness of liver cancer. Overall, these findings validate TRPV2 as a prime candidate for cancer biomarker and future therapeutic target. </p> <h2>Other information</h2> <p>Published in: Disease Markers<br> License: <a href="http://creativecommons.org/licenses/by/4.0" target="_blank">http://creativecommons.org/licenses/by/4.0</a><br> See article on publisher's website: <a href="http://dx.doi.org/10.1155/2020/8892312" target="_blank">http://dx.doi.org/10.1155/2020/8892312</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_4cf3acca03a8d41ab69db7f4c9673215 |
| identifier_str_mv | 10.1155/2020/8892312 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22058789 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | TRPV2: A Cancer Biomarker and Potential Therapeutic TargetKodappully S. Siveen (4246150)Parveen B. Nizamuddin (14590613)Shahab Uddin (14150949)Mohamed Al-Thani (14590614)Michael Paul Frenneaux (14590617)Ibrahim A. Janahi (14070765)Martin Steinhoff (5340194)Fouad Azizi (14152740)Biomedical and clinical sciencesClinical sciencesOncology and carcinogenesisPrecision medicineCancer biomarkersTumor cell growthOncogenicityCancer progressionTherapeutic targetsGenetic alterations<p>The Transient Receptor Potential Vanilloid type-2 (TRPV2) channel exhibits oncogenicity in different types of cancers. TRPV2 is implicated in signaling pathways that mediate cell survival, proliferation, and metastasis. In leukemia and bladder cancer, the oncogenic activity of TRPV2 was linked to alteration of its expression profile. In multiple myeloma patients, TRPV2 overexpression correlated with bone tissue damage and poor prognosis. In prostate cancer, TRPV2 overexpression was associated with the castration-resistant phenotype and metastasis. Loss or inactivation of TRPV2 promoted glioblastoma cell proliferation and increased resistance to CD95-induced apoptotic cell death. TRPV2 overexpression was associated with high relapse-free survival in triple-negative breast cancer, whereas the opposite was found in patients with esophageal squamous cell carcinoma or gastric cancer. Another link was found between TRPV2 expression and either drug-induced cytotoxicity or stemness of liver cancer. Overall, these findings validate TRPV2 as a prime candidate for cancer biomarker and future therapeutic target. </p> <h2>Other information</h2> <p>Published in: Disease Markers<br> License: <a href="http://creativecommons.org/licenses/by/4.0" target="_blank">http://creativecommons.org/licenses/by/4.0</a><br> See article on publisher's website: <a href="http://dx.doi.org/10.1155/2020/8892312" target="_blank">http://dx.doi.org/10.1155/2020/8892312</a></p>2020-12-10T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1155/2020/8892312https://figshare.com/articles/journal_contribution/TRPV2_A_Cancer_Biomarker_and_Potential_Therapeutic_Target/22058789CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/220587892020-12-10T09:00:00Z |
| spellingShingle | TRPV2: A Cancer Biomarker and Potential Therapeutic Target Kodappully S. Siveen (4246150) Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Precision medicine Cancer biomarkers Tumor cell growth Oncogenicity Cancer progression Therapeutic targets Genetic alterations |
| status_str | publishedVersion |
| title | TRPV2: A Cancer Biomarker and Potential Therapeutic Target |
| title_full | TRPV2: A Cancer Biomarker and Potential Therapeutic Target |
| title_fullStr | TRPV2: A Cancer Biomarker and Potential Therapeutic Target |
| title_full_unstemmed | TRPV2: A Cancer Biomarker and Potential Therapeutic Target |
| title_short | TRPV2: A Cancer Biomarker and Potential Therapeutic Target |
| title_sort | TRPV2: A Cancer Biomarker and Potential Therapeutic Target |
| topic | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Precision medicine Cancer biomarkers Tumor cell growth Oncogenicity Cancer progression Therapeutic targets Genetic alterations |